CD19 and acute lymphoblastic leukemia: A meta-analysis conducted on the results of studies published between 1991 and 2014 showed that CAR T CD19 therapy gave the highest response rate in patients with ALL (93%, 95% CI: 65–100%) compared to patients with CML (62%, 95%).